Skip to main content
. 2018 May 29;17:213. doi: 10.1186/s12936-018-2364-8

Table 5.

Malaria case-management practices, by survey round

Round 1
(N = 1162)
Round 2
(N = 1224)
p-value
n (%) n (%)
Composite performance 565 (48.6) 689 (56.3) 0.004
Malaria test done on admission 1, 029 (88.6) 1127 (92.1) 0.080
Malaria test repeated 53 (5.2) 91 (8.1) 0.034
Treatment for test positive severe cases N = 405 N = 465
Artesunate parenteral 283 (69.9) 366 (78.7) 0.030
Quinine parenteral 66 (16.3) 54 (11.6) 0.126
Artesunate and quinine parenteral 35 (8.6) 11 (2.4) 0.003
artemether–lumefantrine 16 (4.0) 26 (5.6) 0.245
Other anti-malarial treatmentsa 2 (0.5) 0 0.168
No anti-malarial treatment 3 (0.7) 8 (1.7) 0.322
Treatment for test positive non-severe cases N = 212 N = 227
artemether–lumefantrine 17 (8.0) 20 (8.8) 0.796
Artesunate parenteral 133 (62.7) 165 (72.7) 0.053
Quinine parenteral 40 (18.9) 32 (14.1) 0.316
Artesunate and quinine parenteral 16 (7.6) 3 (1.3) 0.006
Other anti-malarial treatmentsb 1 (0.5) 3 (1.3) 0.444
No anti-malarial treatment 5 (2.4) 4 (1.8) 0.672
Treatment for test negative severe cases N = 208 N = 240
No anti-malarial treatment 123 (59.1) 149 (62.1) 0.673
Artesunate parenteral 58 (27.9) 71 (29.6) 0.783
Quinine parenteral 14 (6.7) 6 (2.5) 0.128
Artesunate and quinine parenteral 5 (2.4) 1 (0.4) 0.120
artemether–lumefantrine 8 (3.8) 12 (5.0) 0.579
Other anti-malarial treatmentsc 0 1 (0.4) 0.328
Treatment for test negative non-severe cases N = 204 N = 195
No anti-malarial treatment 140 (68.6) 152 (78.0) 0.063
Artesunate parenteral 36 (17.7) 29 (14.9) 0.542
Quinine parenteral 16 (7.8) 7 (3.6) 0.157
Artesunate and quinine parenteral 3 (1.5) 0 0.091
artemether–lumefantrine 9 (4.4) 7 (3.6) 0.639
Treatment for not tested patients N = 133 N = 97
No anti-malarial treatment 54 (40.6) 29 (29.9) 0.110
Artesunate parenteral 45 (33.8) 58 (59.8) 0.002
Quinine parenteral 23 (17.3) 6 (6.2) 0.037
artemether–lumefantrine 10 (7.5) 3 (3.1) 0.147
Artesunate and quinine parenteral 1 (0.8) 1 (1.0) 0.829

a Includes one artemether treatment and one artemether/quinine treatment

bIncludes two DHA-PPQ, one artemether, and one artemether/quinine treatment

cIncludes one artesunate/artemether treatment